EquipNet Celebrates 15 Years of Asset Management

News
Article

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and ManagementPTSM: Pharmaceutical Technology Sourcing and Management-06-04-2014
Volume 10
Issue 6

EquipNet announced its 15th year of supplying asset management services.

EquipNet announced its 15th year of supplying services for the tracking, redeployment, sales or purchasing of second-hand laboratory instrumentation and manufacturing equipment.

EquipNet employees more than 130 people in locations throughout North America, Latin America, Europe, and Asia. EquipNet has provided asset management programs to numerous companies including, Merck, GE Healthcare, Johnson & Johnson, Novartis, Cargill, Mars/Wrigley, Unilever, and Colgate-Palmolive.

Source: EquipNet

Articles in this issue
India Offers Biopharma Opportunities and Challenges
India Offers Biopharma Opportunities and Challenges
Miller_Jim-844459-1408520660149.jpg
Are CMOs Out of Synch With Market Realities?
WEB_SiegfriedSchmitt_New-844461-1408520651300.jpg
Key Considerations for Quality-Technical Agreements
Schniepp_Susan-844458-1408520663253.jpg
Defining Quality Metrics to Ease Drug Shortages
Cocrystals: Industry Takes a Wait-and-See Approach
Cocrystals: Industry Takes a Wait-and-See Approach
DCAT Sharp Sourcing Addresses Procurement Topics
FDA Expands CERSI Network
HPAPIs: Fast-growing Segment Presents Challenges and Opportunities
Turkish Pharma Manufacturers Look to New Markets
Lilly Oncology On Canvas Celebrates 10 Years of Cancer Journeys
BioPlan Associates Releases 11th Annual Global Biomanufacturing Study
BPTF Warns FDA on Reduced API Manufacturer Inspections
EquipNet Celebrates 15 Years of Asset Management
DPx Holdings B.V. Donates to Hospitals and Organizations
Gnosis Receives CEP Certification for Teicoplanin
Recent Videos
Behind the Headlines, Episode 17
Drug Digest: Challenges and Triumphs in Next-Generation Biotherapeutic Development
Related Content
·Mirai Bio and Thermo Fisher are partnering to integrate design, delivery, and CGMP manufacturing for nucleic acid-based therapeutics. ·The collaboration will leverage Thermo Fisher’s RNA and advanced formulations facility to support scalable development of genetic medicines. ·Mirai’s machine intelligence platform will be combined with Thermo Fisher’s technical and manufacturing expertise to streamline drug development workflows.

Mirai Bio and Thermo Fisher Partner to Advance Genetic Medicine Manufacturing

Christopher Cole
May 21st 2025
Article

Mirai Bio and Thermo Fisher partner to integrate AI-driven design with CGMP manufacturing, aiming to streamline development of genetic medicines.

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Feliza Mirasol
April 30th 2024
Podcast

In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.

Abnormal plasma cell or b-cell in multiple myeloma emitting paraprotein 3d illustration | Image Credit: © LASZLO - stock.adobe.com

CellCentric Completes $120 Million Series C Funding Round for Multiple Myeloma Treatment Inobrodib

Patrick Lavery
May 21st 2025
Article

Inobrodib is being developed as a first-in-class oral cancer drug that the company says will be able to treat not only multiple myeloma, but other specific cancers as well.

Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain

Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain

Jill Murphy
November 14th 2023
Podcast

In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.

Coronavirus Covid-19 background - 3d rendering | Image Credit: © Production Perig - stock.adobe.com

EMA Recommends Update to COVID-19 Vaccines for 2025-26 Campaign

Patrick Lavery
May 19th 2025
Article

The LP.8.1 variant of the SARS-CoV-2 virus differs from the JN.1 family that previous vaccines had been designed to target, and has surpassed JN.1 as the variant circulating most widely worldwide.

IRVINE, CALIFORNIA - 16 APRIL 2020: Student Center and Visitor Center Building on the campus of the University of California Irvine, UCI. | Image Credit: © Steve Cukrov - stock.adobe.com

UC Irvine Lab Studies NLRP3 Inflammasome for Inflammatory Disease Treatment Potential

Patrick Lavery
May 19th 2025
Article

Researchers say they have discovered the first drug mechanism that binds to the pyrin domain to block NLRP3 and prevent a series of reactions resulting in inflammation.